Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Pediatric Populations

Slide: 12 of 23

Clinical Questions Addressed by the CER (1 of 3)

In preparing the report on which this continuing medical education activity is based, the authors aimed to answer five Key Questions (KQs). KQs 1 and 2 are listed below:

KQ 1.Prevalence and incidence
KQ 1.1. In children and adolescents aged 18 years or younger, what is the incidence and prevalence of undiagnosed musculoskeletal (MSK) complaints?
KQ 1.2. In healthy children and adolescents aged 18 years or younger, what is the incidence of positive test results for antinuclear antibody, rheumatoid factor, and cyclic-citrullinated peptide?

KQ 2. Natural history
KQ 2.1. What proportion of children and adolescents aged 18 years or younger with undiagnosed MSK pain have pain due to noninflammatory etiologies?
KQ 2.2. What proportion of children and adolescents aged 18 years or younger with undiagnosed MSK pain have pain due to inflammatory etiologies?
KQ 2.3. What proportion of children and adolescents aged 18 years or younger experience symptom resolution or recurrence?